Drug use evaluation of antidyslipidemic agents at a community hospital in Japan

Kazuko Ujita, Keiko Ohno, Masayuki Hashiguchi, Hirotoshi Echizen, Tadaaki Rikihisa, Hiroyasu Ogata

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives: In recent years, the therapeutic implications of dyslipidemias have been clarified in large-scale epidemiologic surveys, and the validity of pharmacotherapy has been established. We investigated the practical realities of pharmacotherapy for dyslipidemias at a community hospital in Japan. Methods: Medical chart surveys were performed retrospectively on 451 dyslipidemic outpatients who visited a community hospital in Japan in July 1997. We collected clinical data from medical charts regarding selected drugs for dyslipidemias, serum lipid levels before drug treatment and after one year of treatment, and risk factors for coronary heart disease (CHD). Results: Regardless of dyslipidemia phenotype, approximately 80% of patients were administered statins. The possibility was raised that physicians recorded risk factors in medical charts incompletely, particularly with regard to family CHD history, smoking, and obesity. Based on Japanese and us guidelines for dyslipidemias, low-density lipoprotein (LDL) cholesterol levels fully satisfied the requirements for initiating pharmacotherapy in the present study. However, the higher the risk of CHD, the lower the percentage of subjects who met the treatment goals defined by both guidelines. Only 23% of patients at high risk for CHD controlled LDLcholesterol sufficiently based on Japanese guidelines. Conclusion: To optimize pharmacotherapy for dyslipidemias, medical staff should assess risk factors for CHD more completely and attempt to achieve full control of serum lipids, particularly in patients at high risk for CHD.

Original languageEnglish
Pages (from-to)499-506
Number of pages8
JournalYakugaku Zasshi
Volume122
Issue number7
DOIs
Publication statusPublished - 2002 Jul
Externally publishedYes

Fingerprint

Drug Evaluation
Community Hospital
Dyslipidemias
Coronary Disease
Japan
Drug Therapy
Guidelines
Lipids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Medical Staff
Therapeutics
Serum
Pharmaceutical Preparations
LDL Cholesterol
Outpatients
Obesity
Smoking
Physicians
Phenotype

Keywords

  • Coronary heart disease
  • Dyslipidemias
  • LDL-cholesterol
  • Pharmacotherapy
  • Risk factors
  • Total cholesterol

ASJC Scopus subject areas

  • Molecular Medicine

Cite this

Drug use evaluation of antidyslipidemic agents at a community hospital in Japan. / Ujita, Kazuko; Ohno, Keiko; Hashiguchi, Masayuki; Echizen, Hirotoshi; Rikihisa, Tadaaki; Ogata, Hiroyasu.

In: Yakugaku Zasshi, Vol. 122, No. 7, 07.2002, p. 499-506.

Research output: Contribution to journalArticle

Ujita, Kazuko ; Ohno, Keiko ; Hashiguchi, Masayuki ; Echizen, Hirotoshi ; Rikihisa, Tadaaki ; Ogata, Hiroyasu. / Drug use evaluation of antidyslipidemic agents at a community hospital in Japan. In: Yakugaku Zasshi. 2002 ; Vol. 122, No. 7. pp. 499-506.
@article{8c8065e791634cf2849c2e7ccb707bc3,
title = "Drug use evaluation of antidyslipidemic agents at a community hospital in Japan",
abstract = "Objectives: In recent years, the therapeutic implications of dyslipidemias have been clarified in large-scale epidemiologic surveys, and the validity of pharmacotherapy has been established. We investigated the practical realities of pharmacotherapy for dyslipidemias at a community hospital in Japan. Methods: Medical chart surveys were performed retrospectively on 451 dyslipidemic outpatients who visited a community hospital in Japan in July 1997. We collected clinical data from medical charts regarding selected drugs for dyslipidemias, serum lipid levels before drug treatment and after one year of treatment, and risk factors for coronary heart disease (CHD). Results: Regardless of dyslipidemia phenotype, approximately 80{\%} of patients were administered statins. The possibility was raised that physicians recorded risk factors in medical charts incompletely, particularly with regard to family CHD history, smoking, and obesity. Based on Japanese and us guidelines for dyslipidemias, low-density lipoprotein (LDL) cholesterol levels fully satisfied the requirements for initiating pharmacotherapy in the present study. However, the higher the risk of CHD, the lower the percentage of subjects who met the treatment goals defined by both guidelines. Only 23{\%} of patients at high risk for CHD controlled LDLcholesterol sufficiently based on Japanese guidelines. Conclusion: To optimize pharmacotherapy for dyslipidemias, medical staff should assess risk factors for CHD more completely and attempt to achieve full control of serum lipids, particularly in patients at high risk for CHD.",
keywords = "Coronary heart disease, Dyslipidemias, LDL-cholesterol, Pharmacotherapy, Risk factors, Total cholesterol",
author = "Kazuko Ujita and Keiko Ohno and Masayuki Hashiguchi and Hirotoshi Echizen and Tadaaki Rikihisa and Hiroyasu Ogata",
year = "2002",
month = "7",
doi = "10.1248/yakushi.122.499",
language = "English",
volume = "122",
pages = "499--506",
journal = "Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan",
issn = "0031-6903",
publisher = "Pharmaceutical Society of Japan",
number = "7",

}

TY - JOUR

T1 - Drug use evaluation of antidyslipidemic agents at a community hospital in Japan

AU - Ujita, Kazuko

AU - Ohno, Keiko

AU - Hashiguchi, Masayuki

AU - Echizen, Hirotoshi

AU - Rikihisa, Tadaaki

AU - Ogata, Hiroyasu

PY - 2002/7

Y1 - 2002/7

N2 - Objectives: In recent years, the therapeutic implications of dyslipidemias have been clarified in large-scale epidemiologic surveys, and the validity of pharmacotherapy has been established. We investigated the practical realities of pharmacotherapy for dyslipidemias at a community hospital in Japan. Methods: Medical chart surveys were performed retrospectively on 451 dyslipidemic outpatients who visited a community hospital in Japan in July 1997. We collected clinical data from medical charts regarding selected drugs for dyslipidemias, serum lipid levels before drug treatment and after one year of treatment, and risk factors for coronary heart disease (CHD). Results: Regardless of dyslipidemia phenotype, approximately 80% of patients were administered statins. The possibility was raised that physicians recorded risk factors in medical charts incompletely, particularly with regard to family CHD history, smoking, and obesity. Based on Japanese and us guidelines for dyslipidemias, low-density lipoprotein (LDL) cholesterol levels fully satisfied the requirements for initiating pharmacotherapy in the present study. However, the higher the risk of CHD, the lower the percentage of subjects who met the treatment goals defined by both guidelines. Only 23% of patients at high risk for CHD controlled LDLcholesterol sufficiently based on Japanese guidelines. Conclusion: To optimize pharmacotherapy for dyslipidemias, medical staff should assess risk factors for CHD more completely and attempt to achieve full control of serum lipids, particularly in patients at high risk for CHD.

AB - Objectives: In recent years, the therapeutic implications of dyslipidemias have been clarified in large-scale epidemiologic surveys, and the validity of pharmacotherapy has been established. We investigated the practical realities of pharmacotherapy for dyslipidemias at a community hospital in Japan. Methods: Medical chart surveys were performed retrospectively on 451 dyslipidemic outpatients who visited a community hospital in Japan in July 1997. We collected clinical data from medical charts regarding selected drugs for dyslipidemias, serum lipid levels before drug treatment and after one year of treatment, and risk factors for coronary heart disease (CHD). Results: Regardless of dyslipidemia phenotype, approximately 80% of patients were administered statins. The possibility was raised that physicians recorded risk factors in medical charts incompletely, particularly with regard to family CHD history, smoking, and obesity. Based on Japanese and us guidelines for dyslipidemias, low-density lipoprotein (LDL) cholesterol levels fully satisfied the requirements for initiating pharmacotherapy in the present study. However, the higher the risk of CHD, the lower the percentage of subjects who met the treatment goals defined by both guidelines. Only 23% of patients at high risk for CHD controlled LDLcholesterol sufficiently based on Japanese guidelines. Conclusion: To optimize pharmacotherapy for dyslipidemias, medical staff should assess risk factors for CHD more completely and attempt to achieve full control of serum lipids, particularly in patients at high risk for CHD.

KW - Coronary heart disease

KW - Dyslipidemias

KW - LDL-cholesterol

KW - Pharmacotherapy

KW - Risk factors

KW - Total cholesterol

UR - http://www.scopus.com/inward/record.url?scp=0036631595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036631595&partnerID=8YFLogxK

U2 - 10.1248/yakushi.122.499

DO - 10.1248/yakushi.122.499

M3 - Article

C2 - 12136647

AN - SCOPUS:0036631595

VL - 122

SP - 499

EP - 506

JO - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

JF - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

SN - 0031-6903

IS - 7

ER -